Modeling Economic Implications of Alternative Treatments Strategies for Acute Bacterial Skin and Skin Structure Infections.
J Med Econ. 2014 Jul 14;:1-30
Authors: Revankar N, Ward AJ, Pelligra CG, Kongnakorn T, Fan W, LaPensee KT
Abstract Objective: The economic implications from the United States (US) Medicare perspective of adopting alternative treatment strategies for acute bacterial skin and skin structure infections (ABSSSIs) are substantial. The objective of this study is to describe a modeling framework that explores the impact of decisions related to both the location of care and switching to different antibiotics at discharge. Methods: A discrete event simulation (DES) was developed to model the treatment pathway of each patient through various locations (emergency department [ED], inpatient, and outpatient) and the treatments prescribed (empiric antibiotic, switching to a different antibiotic at discharge, or a second antibiotic). Costs are reported in 2012 USD. Results: The mean number of days on antibiotic in a cohort assigned to a full course of vancomycin was 11.2 days with 64% of the treatment course being administered in the outpatient setting. Mean total costs per patient were $8,671, with inpatient care accounting for 58% of the costs accrued. The majority of outpatient costs were associated with parenteral administration rather than drug acquisition or monitoring. Scenarios modifying the treatment pathway to increase the proportion of patients receiving the first dose in ED, and then managing them in the outpatient setting or prescribing an oral antibiotic at discharge to avoid the cost associated with administering parenteral therapy, therefore have a major impact and lower the typical cost per patient by 11%-20%. Since vancomycin is commonly used as empiric therapy in clinical practice, based on these analyses, a shift in treatment practice could result in substantial savings from the Medicare perspective. Conclusions: The choice of antibiotic and location of care influence the costs and resource use associated with the management of ABSSSIs. The DES framework presented here can provide insight into the potential economic implications of decisions that modify the treatment pathway.
PMID: 25019580 [PubMed - as supplied by publisher]